Mar 30, 2005 by David NierengartenSoothing Results, But Pain for InvestorsPain Therapeutics delivers again but gets no respect.
Mar 30, 2004 by David NierengartenJumping BiotechsA cancer research conference drives smaller biotechs higher.
Mar 16, 2004 by David NierengartenSanofi Slimming PillSanofi's new drug shows promise for weight loss and smoking cessation.
Mar 9, 2004 by David NierengartenSepracor's No SleeperFDA approval for its sleeping medication sends Sepracor's stock up 70%.
Mar 2, 2004 by David NierengartenGenzyme's Oncology AcquisitionsThe biotech gobbles up two smaller firms for their cancer treatment pipelines.
Feb 24, 2004 by David NierengartenCell Genesys BoostedCell Genesys's shares jump a day late and a dollar higher.
Feb 17, 2004 by David NierengartenAntisense Making Sense?With new antisense drugs in critical trials, David Nierengarten makes the case for companies that stand to benefit.
Feb 10, 2004 by David NierengartenThe Psoriasis WarsThe pharma heavies are battling for the chronic skin disease's market.
Feb 3, 2004 by David NierengartenBig Break for a Small Biotech?Axonyx's new drug for Alzheimer's disease could be first in its class.
Jan 20, 2004 by David NierengartenAdolor's Knocked-Out DrugThe biotech's stock is pummeled after mixed-up trial results.
Jan 13, 2004 by David NierengartenVicuron's Booster ShotWith a new "super-tough" antibiotic, Vicuron's stock is super high.
Jan 6, 2004 by David NierengartenIsis' 2G Drug ShinesWill Isis start making cents from anti-sense drugs?
Dec 23, 2003 by David NierengartenAn Undervalued BiotechNabi Biopharmaceuticals has revenues and a pipeline. Is it undervalued?
Dec 16, 2003 by David NierengartenBiotech's Next PhaseIt's been a great year for biotech, but don't count on a repeat in 2004.
Dec 2, 2003 by David NierengartenHope for Diabetics -- and InvestorsGila monster venom and Amylin Pharma may provide adult diabetics new hope.
Nov 24, 2003 by David NierengartendeCODE's New CodeHas the genomics company deciphered the profitability code?
Nov 5, 2003 by David NierengartenBiotech Unclogs ArteriesEsperion Therapeutics cleaned up arteries in a recent study.
